Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853066 | 0.93 | MMP12 (0.57) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL2953764 | 0.86 | MMP12 (0.64) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL2955843 | 0.86 | MMP12 (0.54) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL3342262 | 0.83 | MMP12 (0.57) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL24286262 | 0.80 | MMP12 (0.49) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL8303156 | 0.80 | MMP12 (0.57) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL18152757 | 0.80 | MMP12 (0.49) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL21552385 | 0.80 | MMP12 (0.49) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL8192799 | 0.80 | NR3C2 (0.51) | MMP12PDE3BPDE3ATP53THRB | |
| SCHEMBL13652221 | 0.78 | MMP12 (0.54) | MMP12PDE3BPDE3ATP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000490-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000490-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170253593-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-09-07 | — | — | US | disclosed |
| US-20170253593-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-09-07 | — | — | US | disclosed |
| US-9695165-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695165-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2015108992-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE AS FGFR4 RECEPTOR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015108992-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE AS FGFR4 RECEPTOR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20150197519-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197519-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-07-16 | — | — | US | disclosed |
| US-8093238-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-01-10 | — | — | US | disclosed |
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| EP-2076512-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008044022-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253593-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | MMP12 1417/4885PDE3B 2921/4885PDE3A 3031/4885 |
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | JAK1, MTOR, MOK | MMP12 3299/4885PDE3B 1250/4885PDE3A 1263/4885 |
| US-10000490-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | MMP12 1417/4885PDE3B 2921/4885PDE3A 3031/4885 |
| US-20150197519-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | MMP12 1417/4885PDE3B 2921/4885PDE3A 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.